ArticleCancer medicine2026
Burden of Middle-Aged and Elderly Patients With Non-Hodgkin Lymphoma From 1990 to 2021: A Systematic Analysis Based on the Global Burden of Disease 2021.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundNon-Hodgkin lymphoma (NHL) is increasingly prevalent in middle-aged and elderly populations, contributing to the rising global health burden, particularly in high-income countries.
methodsThis retrospective analysis utilized data from the Global Burden of Disease (GBD) study (1990-2021) to examine temporal trends in age-standardized incidence, mortality, and disability-adjusted life year (DALY) rates of NHL among middle-aged and older adult populations, incorporating age- and sex-stratified comparisons. Furthermore, projections for the subsequent 30 years were generated using Bayesian age-period-cohort (BAPC) modeling.
resultsFrom 1990 to 2021, the number of cases, deaths, and DALYs in middle-aged and older people with NHL had significant increases. Age-standardized incidence rates exhibited an increasing trend (estimated annual percentage change [EAPC] = 0.53), whereas mortality (EAPC = -0.33) and DALY rates (EAPC = -0.52) demonstrated a decreasing trend. The Western European region and high SDI countries are the core burden areas for middle-aged and elderly populations with NHL globally. Lower-middle SDI countries experienced the fastest increase in mortality (EAPC = 0.38) and DALY rates (EAPC = 0.22), while high-SDI countries experienced the steepest decline in all metrics. The DALY burden showed its peak value at 65-69 years among middle-aged and aged adults with NHL, while the morbidity and mortality burden reached their highest point at 70-74 years. When stratified by gender, the overall burden was higher in males than in females. High BMI causes the burden of NHL DALY to rise with increasing SDI, up to 39.14% in High-income North America. By 2050, global NHL incidence is projected to increase modestly by 0.28%, whereas mortality and DALY burdens are expected to decline markedly by 30.67% and 23.02%, respectively.
conclusionsNHL in middle-aged and older adults represents a significant global public health burden, necessitating context-specific interventions due to variations across regions, genders, and age groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.